Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Intra-Cellular Ther (ITCI)

Intra-Cellular Ther (ITCI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,998,081
  • Shares Outstanding, K 106,328
  • Annual Sales, $ 680,850 K
  • Annual Income, $ -74,680 K
  • EBIT $ -117 M
  • EBITDA $ -125 M
  • 60-Month Beta 0.69
  • Price/Sales 20.55
  • Price/Cash Flow N/A
  • Price/Book 12.15

Options Overview Details

View History
  • Implied Volatility 5.70% ( -0.69%)
  • Historical Volatility 7.00%
  • IV Percentile 1%
  • IV Rank 0.89%
  • IV High 115.58% on 04/15/24
  • IV Low 4.71% on 03/05/25
  • Put/Call Vol Ratio 0.12
  • Today's Volume 118
  • Volume Avg (30-Day) 895
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 63,480
  • Open Int (30-Day) 58,713

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate 0.04
  • Low Estimate -0.20
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
128.04 +2.82%
on 02/26/25
131.67 -0.02%
on 03/21/25
+3.05 (+2.37%)
since 02/21/25
3-Month
80.82 +62.88%
on 01/07/25
131.67 -0.02%
on 03/21/25
+48.20 (+57.76%)
since 12/20/24
52-Week
64.09 +105.41%
on 05/20/24
131.67 -0.02%
on 03/21/25
+63.27 (+92.53%)
since 03/21/24

Most Recent Stories

More News
Intra-Cellular: Q4 Earnings Snapshot

Intra-Cellular: Q4 Earnings Snapshot

ITCI : 131.65 (+0.04%)
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results

ITCI : 131.65 (+0.04%)
J&J Stock Up More Than 6% in a Month: Time to Buy, Sell or Hold?

J&J JNJ stock has risen more than 6% in the past month. The reason behind the increase was a strong-than-expected fourth-quarter earnings report and an optimistic outlook for the Innovative Medicine segment...

ITCI : 131.65 (+0.04%)
JNJ : 163.63 (+0.37%)
KVUE : 23.31 (-0.34%)
AMGN : 316.04 (+0.32%)
How to Play J&J Stock After Q4 Beat & Soft 2025 Sales Guidance

Key TakeawaysJNJ beat Q4 earnings and sales estimates, with its Innovative Medicines Unit outperforming expectations.Sales in the unit rose 4.4% YOY to $14.33 billion, led by key drugs such as Darzalex,...

ITCI : 131.65 (+0.04%)
JNJ : 163.63 (+0.37%)
KVUE : 23.31 (-0.34%)
AMGN : 316.04 (+0.32%)
J&J's Q4 Earnings Beat, Stock Down on Tepid 2025 Sales Guidance

Johnson & Johnson’s JNJ fourth-quarter 2024 earnings came in at $2.04 per share, which beat the Zacks Consensus Estimate of $2.00. Earnings declined 10.9% from the year-ago period. Adjusted earnings...

ITCI : 131.65 (+0.04%)
JNJ : 163.63 (+0.37%)
KVUE : 23.31 (-0.34%)
AMGN : 316.04 (+0.32%)
Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Earnings?

Key TakeawaysThe Zacks Consensus Estimate for JNJ Q4 sales and earnings is $22.5 billion and $2.01 per share, respectively.JNJ's performance has impressed, as the company exceeded earnings expectations...

ITCI : 131.65 (+0.04%)
JNJ : 163.63 (+0.37%)
KVUE : 23.31 (-0.34%)
AMGN : 316.04 (+0.32%)
MarketBeat Week in Review – 01/13 - 01/17

The sell-off in stocks reversed abruptly this week on better-than-expected inflation readings; investors will want to see strong earnings to support the rally

TGT : 104.06 (-0.13%)
NVDA : 117.70 (-0.70%)
SNOW : 158.39 (+0.76%)
F : 10.00 (-0.10%)
JPM : 241.63 (+1.10%)
JNJ : 163.63 (+0.37%)
NKE : 67.94 (-5.46%)
RGTI : 9.07 (+0.89%)
GS : 565.14 (+0.44%)
MCD : 305.44 (-0.51%)
LCID : 2.42 (+6.14%)
SOUN : 9.86 (+2.82%)
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?

JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractive

ITCI : 131.65 (+0.04%)
JNJ : 163.63 (+0.37%)
The Zacks Analyst Blog Highlights J&J, Eli Lilly, GSK and Intra-Cellular

For Immediate ReleaseChicago, IL – January 15, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

ITCI : 131.65 (+0.04%)
JNJ : 163.63 (+0.37%)
LLY : 837.57 (-0.59%)
GSK : 39.24 (-0.43%)
Stock market today: Wall Street mostly rises after encouraging inflation data despite Lilly's drag

Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks kept indexes in check

META : 596.25 (+1.75%)
NVDA : 117.70 (-0.70%)
AAPL : 218.27 (+1.95%)
C : 71.98 (+0.22%)
$SPX : 5,667.56 (+0.08%)
JPM : 241.63 (+1.10%)
JNJ : 163.63 (+0.37%)
HEES : 95.03 (-0.05%)
M : 13.24 (-0.97%)
$IUXX : 19,753.97 (+0.39%)
URI : 628.16 (-0.40%)
SIG : 58.06 (+3.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular...

See More

Key Turning Points

3rd Resistance Point 131.87
2nd Resistance Point 131.77
1st Resistance Point 131.71
Last Price 131.65
1st Support Level 131.55
2nd Support Level 131.45
3rd Support Level 131.39

See More

52-Week High 131.67
Last Price 131.65
Fibonacci 61.8% 105.85
Fibonacci 50% 97.88
Fibonacci 38.2% 89.91
52-Week Low 64.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar